Term
| who receives hepA vaccine? |
|
Definition
| children >1yo, travelers, medical personnel, military personnel |
|
|
Term
| for which hep viruses do we have vaccines for? |
|
Definition
|
|
Term
| MOA of action of lamivudine, telbivudine, adefovir, tenofovir, entecavir |
|
Definition
| inhibits DNA polymerase/RT, chain terminator |
|
|
Term
| active form is the triphosphate form |
|
Definition
|
|
Term
| active form is the diphosphate form |
|
Definition
|
|
Term
| indicated for lamivudine-resistant strains of hepB |
|
Definition
|
|
Term
|
Definition
| lamivudine, telbivudine, adefovir, tenofovir, entecavir |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| renal impairment, reduced bone density |
|
|
Term
|
Definition
|
|
Term
|
Definition
| increases half life, decreases clearance |
|
|
Term
|
Definition
| sulfasalazine, balsalazide, olsalazide |
|
|
Term
| indications for sulfasalazine, balsalazide, olsalazide |
|
Definition
|
|
Term
| time release capsule best for distribution throughout small intestine |
|
Definition
|
|
Term
| pH sensitive drug best for absorption in terminal ileum and colon |
|
Definition
|
|
Term
| indication and administration for hydrocortisone |
|
Definition
| UC; topical, foam suppository |
|
|
Term
| indication and administration for budesonide |
|
Definition
|
|
Term
| delayed therapeutic response takes weeks to months |
|
Definition
| purine analogs: 6-mercaptopurine or azothioprine |
|
|
Term
| AE: dose-dependent bone marrow suppression; indicated for Crohn's |
|
Definition
|
|
Term
| AE: megaloblastic anemia; indicated for Crohn's |
|
Definition
|
|
Term
| AE: risk of URI, TB reactivation |
|
Definition
|
|
Term
| fully humanized anti-TNFa |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| lactobacillus, bifidobacterium |
|
|
Term
| antibiotics used for Crohn's Disease |
|
Definition
| metronidazole, ciprofloxacin, clarithromycin |
|
|
Term
| drugs specifically indicated for Crohn's |
|
Definition
| budesonide, methotrexate, adalimumab, infliximab, certolizumab pegol, antibiotics, probiotics |
|
|
Term
|
Definition
|
|
Term
|
Definition
| antispasmodic; anticholinergic |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| cardiovascular side effects |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| decreases cholesterol content and dissolves gallstones |
|
|
Term
|
Definition
| 5-HT4 receptor agonist; increases peristalsis and Cl- secretion |
|
|
Term
| resistance occurs in up to 50% of patients who have been on treatment for 3 years |
|
Definition
|
|
